Link to the announcement from Clinerion CEO Barış Erdoğan >
Link to the announcement of the merger of Citeline and Norstella >

With the integration into Citeline, Clinerion has the opportunity to access tools and services complementary to our own, expanding the portfolio of offers, as well as access to experts and expertise along the entire clinical intelligence, planning, development and trials process streams. This will allow us to continue to develop cutting-edge technologies and expand our real-world data network. 

Our joining Citeline and the Norstella group is excellent news for you, our partners and customers, who will benefit from our combined expertise, a wider portfolio of products, faster innovation, and enhanced capabilities, providing even greater value to your business over time. In the meantime, Clinerion will continue to provide the outstanding customer service you have come to expect, and your interaction with our business will continue as usual.

Link to the announcement from Clinerion CEO Barış Erdoğan >
Link to the announcement of the merger of Citeline and Norstella >

Mount Lebanon Hospital University Medical Center - MLHUMC is a hospital in the city of Hazmieh, Lebanon, with a 400-bed capacity and specializing in cardiology, oncology, rare diseases, diabetes, dermatology, surgery, imaging, critical care and endocrinology, with 12 pediatric life support (PLS) stations. As a clinical trial site, MLHUMC performs 59 trials per year.

Using the Clinerion Federated Machine Learning Platform, users can train models on local data to identify pattern in local patient cohorts, and further optimize models by using data from multiple sites. For RWD, it can be used to develop detailed models based upon all possible heterogenous disease presentations and novel predictive biomarkers, enabling the prediction of high risk in patients before they reach critical state, as well as the generation of disease phenotype sets for the identification of undiagnosed diseases, e.g., to find rare disease patients.

See more about our Federated Machine Learning Platform >

Ensuring Drug Safety, First and Foremost, Even Ahead of Drug Efficacy:
In the commercialisation of new medications, the paramount legal responsibilities of the pharmaceutical company are, firstly, to prove that the pharmacology is safe and well understood, and, secondly, to prove  effectiveness against the targeted disease ...

Link to the article in Journal for Clinical Studies, Volume 14, Issue 5 >

Read the article >

“Clinerion is looking forward to a great collaboration with SCRS as a GIP member, based on our mutual principles of supporting clinical trial sites with access to trials, improving trial efficiency and sharing best practices,” said Luis Magalhaes, Clinerion’s Customer Solutions Director. “Clinerion’s worldwide network of hospitals can benefit greatly from SCRS’ expertise and we expect SCRS will benefit from Clinerion’s global reach as they expand beyond the USA. We have great expectations of our contacts with SCRS sites and the other GIP members.”

More information on our Partners page >

Highlights:

• ANID is based on fully de-identified patient records, with no use of pseudo-IDs.
• Newly patented technology uses a combination of techniques to match de-identified records with corresponding hospital medical records.
• Newly patented system set-up increases data security and privacy protection.
• The newly patented technology uses de-identified records, but enables the duly authorized clinical trial manager at the hospital to identify eligible clinical trial candidate patients.
• Technology has been in use in the Patient Network Explorer hospital network since 2017.
   

The newly patented ANID technology, implemented in the hospitals in Clinerion’s global hospital network on Patient Network Explorer since 2017, significantly increases the security of private information when using patient medical records to evaluate study feasibility, or identifying patients for enrollment in clinical trials.

The three newest Brazilian hospitals to join the global community of partner hospitals on Clinerion’s Patient Network Explorer platform are:

• Santa Casa de Misericórdia, Belo Horizonte, Minas Gerais
• Hospital Tacchini, Bento Gonçalves, Rio Grande do Sul
• UOPECCAN – União Oeste Paranaense de Estudos e Combate ao Câncer, also known as the Hospital do Câncer, Cascavel, Paraná
   

“We have always said that patients are at the center of everything that we do, and we are pleased to have established a strong coverage in Brazil to support patients in the country,” says Barış Erdoğan, CEO of Clinerion. “As we expand, we become able to offer more and more real-world data useful for the development of next generation treatments and procedures.”

We are happy to share Sinan Findik's new article (only in Turkish for now) in which he defines the main areas where we can benefit from electronic health records (EHRs), draw attention to the potential use of EHRs in preventive health, and present examples where we can benefit more from EHRs in clinical decision support systems in parallel with the increasing impact of artificial intelligence (AI) and innovative biomedical approaches. Our article also includes a real-world evidence (RWE) example of patients who have come to the hospital for a general examination with Clinerion's Patient Network Explorer to make it more understandable what information we can use and how.

In this article (for now, only in Turkish) Clinerion's Sinan Findik summarizes our new preventive health service model, created using EHRs.

Sinan's article is on page 27.

Link to the original article (in Turkish) >

"Industry Clinical Trials in Poland. Possibilities to increase number and scope of trials in Poland." is a report sponsored by the Polish Association of Innovative Pharmaceutical Companies (INFARMA) and the Polish Association for Employers of Contract Research Organizations (POLCRO). Clinerion was invited to contribute a chapter on "Harnessing the Power of Electronic Health Records to Increase Speed and Precision of Clinical Trials."

Download the report here (page is in Polish, but an English language report is available) >

Machine Learning (ML) and Artificial Intelligence (AI) have come to the forefront of data analytics with the promise of generating new medical insights. However, for healthcare data, patient data security is paramount due to the GDPR and similar regulations. Traditional methods of data consolidation for Machine Learning / AI modelling into a single warehouse or a data lake are often not possible even with anonymized data due to data protection rules. The new, emerging alternative is a federated in situ data analytics construct in which healthcare data are anonymized within the care facility and accessed via a secure cloud application. This paper demonstrates how this ensures data security within the original data domain, while allowing analytics for modelling and AI to be applied in a federated fashion.

"The meaning of Clinical Trials for humans has recently changed significantly, “evolved”, so to speak. In today’s environment, where ethical validity is much more strictly controlled, this meaning is far beyond “human drug testing” and much closer to the “therapeutic goal”. The number of clinical trials in western countries that have perceived this change has increased rapidly and continues to increase. Although the number of clinical studies in the MENA region is increasing day by day, it is still far from its potential. Among the reasons for this are legal, technological, ethical, epidemiological, educational and economic factors. This book presents both the difficulties encountered in conducting clinical trials in MENA and
suggestions for solving these difficulties."

Fatih Özdener has broad pharmaceutical industry experience at different local and regional medical functions including clinical operations, clinical quality and medical management in Turkey, Middle East and Africa. He has more than twenty publications in the fields of molecular and clinical pharmacology. Currently, he is a faculty member and a member of management board at Bahcesehir University School of Medicine and the program coordinator of Pharmaceutical Medicine master’s degree program at the same university.

More details and ordering >

"The next few years will see the development of natural language processing capabilities to capture the physician’s diagnostic interpretation, digitally, from their patient notes, as well as AI or ML capabilities to research and model the patient journey and understand the critical steps and timepoints in diagnosis and treatment as well as patient stratification. It is an exciting time to be in digital healthcare and be patient care and outcomes-focused."

Read the interview at The Evidence Base >

"Real World Data is entirely about perspective. What health data is needed to answer your question? RWD now encompasses the entire pharmaceutical process from discovery and development into clinical research and commercialization. The specifc question requires a specifc answer and thereby a specifc data capability to answer. EHR data, such as Clinerion´s, help in pre-clinical and clinical understanding of patient journey and outcomes and improving outcomes."

Link to the article in Journal for Clinical Studies, Volume 13, Issue 6 >

"To enable faster access to innovative medical interventions for patients and physicians, part of the strategic approach must be unlocking the full scope of usable, useful information from patient electronic health records (EHR) to generate productive real-world data."

This article is taken from International Clinical Trials November 2021, pages 76-80. © Samedan Ltd.

Link to the article in International Clinical Trials November 2021 >

Clinerion was selected by the Swiss Personalized Health Network (SPHN) to be the backbone of its Federated Query System (FQS) due to the unique nature of its patented federated cloud infrastructure, which allows patient data to remain inside the IT infrastructure and under the control of each hospital, while still allowing queries of anonymized and obfuscated patient data from other hospitals in the network.

More on Clinerion's collaboration with the SPHN > 

Hospital Pablo Tobón Uribe is a general hospital with 483 beds, offering all the key medical specializations to the catchment area around Medellin, Colombia. The hospital runs 72 clinical trials per year. The hospital is notable for its academic and clinical research expertise, as it is also a University Hospital that is invested in the education of medical students and in innovating in scientific areas and infrastructure.

“Grupo NotreDame Intermédica is our 21st hospital group partner in Brazil, bringing our Brazil coverage north of 10 million patients,” says Barış Erdoğan, CEO of Clinerion. “We can truly say that we have the largest coverage on Brazil for EHR-based search. Once again, we thank iHealth Group for their continued support for the Clinerion Community of hospitals in Brazil.”

The new Clinerion patent underpins any medical EHR database infrastructure that incorporates a hybrid model of cloud-and-local server node installations at individual hospitals, as well as any method for search of patient cohort care metrics across such a platform. This allows real-time search at each individual hospital across the entire network at once, returning aggregate metrics from the entire network. This technology forms the basis of Clinerion’s Patient Network Explorer.

Overview of Clinerion patents >

At the recent DIA 2021 Global Annual Meeting, we asked booth visitors to to let us know their thoughts on the following topics - and they they didn't disappoint!

• What is most important to your data analytics?

• What trends in real-world data do you see having the biggest impact in clinical research and/or healthcare in general in the next 5 years?
   

Find out the results >

Event details >

Supporting epidemiological research, RWD RADAR generates patient cohort aggregate metrics, as well as offers metrics on the patient journey, from diagnosis to treatment modalities, and geographically, all based on real-world data available on Clinerion’s Patient Network Explorer platform. Patient cohort aggregate metrics show insights on disease-treatment relationships and disease-disease relationships, and are visualized as Top N lists, ranking the related concepts within a field code with the highest patient hits.

The statistics are based on real-time data and available with timestamps, allowing the generation of an incidence timeline. Data may be visualized aggregated, or geographically mapped, as well as showing gender and age distributions.

RWD RADAR can be used for epidemiology studies to look at disease occurrence, treatment metrics, differences by hospital, region and country, as well as to identify differential treatment groups or cohorts by location, procedure or medication (segmentation by different treatment options and/or by drug/drug class). As Clinerion’s patient network expands, this will provide deep insights into hard-to-find patient groups, locations and countries within the network.

Find out more about RWD RADAR >

Contact us to get a demo >

Find out more and access the poster >

Access to electronic health data has never been so crucial both for Latin American healthcare systems as well as for its economies, as evidenced right now during the time of COVID-19. We outline the issues and challenges encouraging digitalization and the benefits it can bring, in particular, for accelerating recruitment for clinical trials, and tracking epidemiology of diseases within and across regions and populations.

Clinical Research Insider website >

The four newest Brazilian hospitals to join the global community of partner hospitals on Clinerion’s Patient Network Explorer platform are:

• Hospital São Lucas – PUCRS, Porto Alegre, Rio Grande do Sul
• Hospital Martagão Gesteira, Salvador, Bahia
• Hospital Ana Nery, Salvador, Bahia
• Centro Regional Integrado de Oncologia (CRIO), Fortaleza, Ceará

They are projected to go online in Patient Network Explorer by the end of May, 2021.

Nadine Abdelhadi has expertise in the fields of clinical pharmacy, biochemistry, pharmacoeconomics, clinical research, innovation, intellectual property, and commercialization.

“Joining Clinerion, I aim to improve patient care through high-quality clinical research,” she says.

Clinerion Research Ambassadors are brilliant scientists around the world who have significant experience in their area and conduct advanced long-term research projects in clinical research, RWE or related scientific fields. 

Our inspiring, vital message is powerful and simple! We work to help health professionals connect with research opportunities. Through the Clinerion Research Ambassadors, we aim to promote research throughout our Clinerion community; at the partner institutions, and among the individual members, their peers and colleagues.

Clinerion and Medexprim will set up a joint offering which allows access to de-identified, enriched, longitudinal data points derived from complex medical data sets, which combine electronic health records and their corresponding clinical images, to improve research and help patients receive better care. This collaboration will accelerate and expand Clinerion’s and Medexprim’s networks of hospital partners and accelerate the implementation of a clinical data warehouse globally accessible via a proprietary cloud.

"CEO Baris Erdogan explains how the company is creating and applying technology to significantly reduce the drug development timeline. Clinerion uses Big Data analytics technologies to help hospitals, pharmaceutical companies and research organizations identify high-risk patients for different diseases, improve the market access process, respecting privacy laws and regulations along the way."

Read the interview at Pharma Boardroom, the global platform for C-Level healthcare & life sciences executives >

The following article is translated from the Portuguese and was originally published in Setor Saúde.
Go to the original article >
 

Institution incorporates Clinerion's Patient Network platform

The Santa Casa de Porto Alegre currently conducts 110 clinical studies sponsored by the pharmaceutical industry in the areas of cardiology, oncology, nephrology, pneumology, infectious diseases, pulmonary hypertension, pediatrics, endocrinology and intensive care. These are studies that seek new treatments, able to control patients' symptoms, cure and prevent disease, and restore people's health. In order to facilitate the capture of patients eligible to participate of these studies, Santa Casa incorporated the Patient Network platform, which combines sponsors' study protocols with anonymous patient data in the hospitals of Clinerion, a Swiss-based company that accelerates clinical research and medical access to treatments for patients.

At Santa Casa, the tool is integrated with Tasy, a medical record system that gathers information from all patients in the nine hospitals that make up the institution, in order to facilitate the participation of these patients in clinical studies.

“Clinical research is aimed at improving the quality of life of people. Participation in the research reaches a greater number of people who may benefit, either through treatments aimed at their recovery, as well as improving health problems,” says Antônio Kalil , medical director of Santa Casa.

As explained by the Teaching and Research coordinator at Santa Casa, Roberta de Almeida da Silva, before the implantation of tool, which is being conducted by iHealth - a company focused on serving the health informatics sector - the search for patients for participation in clinical studies was manual, through electronic medical records and the ICD: “The results, many times, were compromised due to possible record failures, in addition to taking much longer, when in fact the process should be finished with agility.”
 

International patient privacy rules and data security

According to Santa Casa, the process involves the analysis of Big Data provided by Clinerion, leveraging real-time data from electronic health records that meet international regulations on patient privacy and data security, enabling the Teaching and Research sector of Santa Casa de Porto Alegre the necessary support to constant expansion in their research.

After a three-year tenure, Clinerion’s current CEO, Ian Rentsch, has decided to step down for personal reasons and to return to his family in Berlin by the end of January, 2021.

"Rare diseases are rare by nature; they often present heterogeneously, and patients may be diagnosed late or incorrectly at first. Because of the complexity and differential symptom presentation by individuals with rare diseases, their RWD – from their electronic records – are often the best and only resource to understand these patients’ journeys and how their conditions have and continue to develop/evolve."

Read the interview at The Evidence Base >

"The volume and diversity of digital data is exploding, and, in healthcare, the number of electronic medical records is growing exponentially as technology makes this information increasingly available. Real-world data is increasingly accessible and useful for outcomes research and regulatory purposes. While clinical trial evidence remains the gold standard for evaluation of treatment efficacy, there is increasing interest and potential for converting RWD into real-world evidence that, through analysis and interpretation, can be used to inform healthcare decision-making."

This article was written with the support of our partners, Volv.

"COVID-19 research is hungry for immediate access to real-world data to gain insights. Digital health technologies that enable continuous, real-time data collection meet this need. Across COVID-19 clinical trials, social-distancing measures force widespread use of virtual connectivity, and remote monitoring and management. So, we are likely to see real acceleration in the uptake of new technologies and process.

"These technologies can significantly reduce the time, effort, and burden on investigators, clinical research centers, and participants. The industry has been discussing these benefits for years, but with the traditional ecosystem at a standstill, COVID-19 powers the adoption of digital and virtual technology."

Link to the article in Clinical Research Insider, No. 2 >

Clinerion and Maxer will cooperate to engage clinical trial sponsors to fully exploit Patient Network Explorer’s potential and provide added-value services arising from Maxer’s experience in clinical data management, regulatory affairs, medical affairs, clinical trial disclosure and data transparency, and medical writing services.

The partners' joint mission is to liaise with study sites to increase patient participation in trials to its full potential by offering tools to optimize protocol design, supporting the efficient start-up of local trials, and planning and consistently hitting realistic patient recruitment targets to enable the achievement of total timeline targets.

More than eighty percent of trials are delayed and approximately thirty percent of sites never enroll patients because of limited access to patients who match the study criteria. The combination of Clinerion’s expertise in leveraging real-time, real-patient, and real-world electronic health record (EHR) data for clinical research combined with Trialbee’s unique multiple step qualification process, which includes online qualification and nurse practitioner interviews to ensure high-quality patient matches prior to obtaining consent and enrollment, will significantly improve and streamline this process. The Trialbee platform provides full transparency of the status of the referred patient flow throughout the entire clinical trial and continuously offers sites and sponsors full insight into the effectiveness of recruitment strategies.

Health Trends' research activities focus on digital health, trends, and new technologies in the context of the Swiss healthcare system.

"This is a great recognition as it acknowledges our capacity as an established organization to innovate in an uncertain and changing environment, in difficult times," says Ian Rentsch, Clinerion CEO. "We will continue to provide the best real-world data analysis and patient recruitment tools to support all pharma stakeholders so they can navigate today’s uncharted waters.”

Download the full-sized map from Health-Trends >

To protect Patient Network Explorer user accounts from breach, Clinerion is activating a second verification step during the sign-in process. In addition to the password, Patient Network Explorer now includes an authorization step that will run via the “Clinerion PNEx Authenticator” smartphone app.

The “Clinerion PNEx Authenticator” smartphone app is available now on the Apple App Store and on the Google Play Store, in English, Chinese, French, German and Italian.

Clinerion PNEx Authenticator in the Google Play Android Store: https://play.google.com/store/apps/details?id=com.clinerion.pnex.accessapp
Clinerion PNEx Authenticator in the Apple App Store: https://apps.apple.com/us/app/clinerion-pnex-authenticator/id1521800088

The competition highlights companies that demonstrated innovative solutions, technologies, and services that have the potential to make the greatest impact for biotech and pharma companies. Clinerion was recognized as a finalist in the category of  Data Analytics/Business Intelligence.

Clinerion was selected as a finalist for its innovative, industry-leading real-world data service solutions for the generation of real-world evidence (RWE) and health economics and outcomes research (HEOR) on its Patient Network Explorer platform, in particular for real-world data for COVID-19.

In the battle against COVID-19, researchers and health authorities require immediate patient data from a global perspective on disease transmittance, cohorts, and success rates for treatment regimes, among many other indicators. Patient Network Explorer supports research and RWE for COVID-19 cases, as well as for conditions that are associated with SARS-CoV-2 infections.

Fierce Innovation Awards website >

We are pleased to receive this award in "EHR Innovation"!

All nominees were to address the question – “How does your company or product break through the crowded MedTech market?” and the evaluation criteria for the MedTech Breakthrough Awards program were focused around the concept of innovation. 

Per the judging process, all award nominations were fully analyzed, evaluated and scored by MedTech Breakthrough's expert panel of judges, representing a mix of technical, business, academic and marketing expertise within the industry.

View all 2020 winners via MedTech Breakthrough's website: https://medtechbreakthrough.com/ >

Our healthcare is becoming increasingly interconnected as technologies allow us to be more connected to our devices, to other people and healthcare services and providers. Our healthcare footprint is now part of our digital footprint.
Our digital footprint is now part of a larger ecosystem that promises to enable better patient care through better insights.

The challenge is to enable while also maintaining individual privacy and data security.

Read the full article by clicking the link below.

The Diagnostic and Consultative Center “Ascendent” Ltd., Sofia, Bulgaria, performs outpatient clinical trials for bioavailability and bioequivalence studies. DCC Ascendent conducts examinations, non-invasive procedures and clinical trials in obstetrics and gynecology, neurology, endocrinology, psychiatry, psychology, dermatology, pulmonology, and hematology.

The clinic has twelve beds and has been consecrated to conducting clinical trials and investigating new treatments for more than 15 years, performing 15-16 clinical trials per year. They follow GCP guidelines and have been inspected by the FDA and BfArM, as well by other competent authorities.

Ege University Hospital serves as the largest hospital in the western part of the country, with 1,896 beds. Beyond Turkey itself, the university hospital provides services throughout the neighboring countries, as well as the Balkans and the Caucasus, with its experienced team and state-of-the-art equipment.

EDIT: the number of beds at Ege University was incorrectly reported in the original release dated 2nd July, and has been updated

"In the field of clinical research, the therapeutic area of oncology in particular is facing a substantial patient recruitment challenge. At present, roughly 15,000 oncology trials are actively recruiting (Longtaal Clinical Trials Landscape Dashboard; www.clinicaltrials.gov), while participation rates have been estimated at a mere 3%-8% of possible candidates, with even smaller numbers in minority and geriatric populations (Institute of Medicine [US] Forum on Drug Discovery, Development, and Translation, 2010). Low enrolment rates threaten more than just the success of individual clinical trials: they may also hinder treatment advances and corresponding benefits to outcomes (Unger et al., 2016).

"Improving cancer care for patients in all aspects is the most important outcome promised by trials, but the fact is that any success stories happen in defiance of competition for patients among oncology researchers and of barriers of protocol feasibility and patient eligibility."

Link to the article in Clinical Research Insider, No. 2 >
Link to the article in our Expert Corner >

Effective immediately, users of Clinerion’s Patient Network Explorer can review detailed clinical trial statistics on an individual hospital level. Derived and mapped from multiple public sources, this new functionality allows for browsing, filtering, reviewing, and comparing site trial performance statistics, including breakdowns on studies by sponsor, by condition, by trial phase and by recruitment status.

The possibility to further filter by study status, sponsor, phase, or condition offers detailed results and a list of the respective studies which provides more information such as on other locations where the study is being conducted.

More details >

Among the criteria which were used to select the award winners were the company's history, services, products, presence within the industry, articles, and social media presence.

We are very pleased to receive this award which highlights our willingness and successful efforts to support and accelerate clinical research, using real-world patient data and innovative approaches. 

Read the full press release via GHP's website: GHP Biotechnology Awards 2020 Winners Announcement

Joining Patient Network Explorer, EVEX Hospitals’ patients and their treating physicians gain increased treatment options and quicker access to new medical interventions. Patients will be matched to clinical studies according to their electronic health records, ensuring better screening when recruiting for clinical trials. Trial managers gain the ability to include eligible patients for trials more quickly and efficiently than before.

“This certification is a great validation of the vital importance Clinerion places on having rigorous and meaningful business processes, in support of our work developing our software and services for the future,” says Barış Erdoğan, Vice President Site & Patient Networks, Clinerion. “Clinerion has been on this journey for a while, recently gaining ISO 27001:2013 certification, confirming that we are following best practice information security principles.

For the 2020 edition of this fact sheet, our CEO Ian Rentsch was interviewed by S-GE and Clinerion is mentioned as a key example of a thriving life sciences SME.

View fact sheet via S-GE website >

“We are very pleased to receive this certification, which reflects the fact that Clinerion’s information security management system is part of and integrated with our processes and overall management structure,” says Ian Rentsch, CEO of Clinerion. “For Clinerion, information security is considered in the design of processes, information systems, and controls. Our implementation of our information security management system can be scaled in accordance with the needs of the organization.”

"Hospital PUC-Campinas Celso Pierro is a reference hospital in high-complexity care in Campinas, São Paulo, and surrounding regions, with 339 beds. The hospital runs clinical trials in cardiology, dermatology, endocrinology and haematology, among others.

"By joining the Patient Network Explorer platform, patients at Hospital PUC-Campinas Celso Pierro will gain visibility when sponsors are seeking patient cohorts and selecting sites for clinical trials. Patient Network Explorer matches sponsors’ trial protocols to the anonymized EHR data of patients in Clinerion’s hospital network."

"Together, the partners’ joint mission is to increase patient participation in studies to its full potential by optimizing protocol design, enabling study sites to efficiently start up their trials locally and plan and meet realistic patient recruitment and therefore total timeline targets.

"This new clinical trial optimization partnership also facilitates a total study site network activation for all trials, beyond the study sites already chosen to participate, by facilitating online referral and activation services.

"Both iClusion and Clinerion maintain cloud platforms which bring together participants from across the clinical study ecosystem, comprising sponsors, hospitals and clinicians, and treating physicians and patients. However, the partners offer complementary support and solutions throughout the product development process."

UPDATE: The European Site Solutions Summit is postponed.  We will forward more details when we get them.

"Wefight’s Vik is a virtual companion supporting patients through their healthcare pathway. Vik brings patients appropriate support at the right time and engages patients over the long run. The app provides consented patients with a platform to gather information about their disease. Through partnership with Clinerion, Vik will now also leverage both retrospective data at the hospital level and direct-to-patient prospective data to identify, engage and recruit patients to participate in the most appropriate clinical trials, according to the trials’ protocol criteria."

"The synergy that follows from the combination of Clinerion’s RWD and Datametrix’s analytical capabilities supports pharmaceutical companies with optimization of clinical study design to meet strategic development needs while reflecting real patient populations, where the patients are. It helps pharma customers drive successful recruitment by being able to select sites that see a sufficiently large population of potentially eligible patients; and then also helping those sites directly identify the eligible patients. It also enables improvement in the accuracy of RWD comparative clinical studies by applying statistical models to define the RWD study end points. Clinerion can use their access to RWD data to recruit patient to RWD comparative arms."

“We are pleased that this collaboration will bring many benefits to the Karadeniz Technical University Farabi Hospital,” says Dean Prof. Dr. Mustafa Imamoğlu, “Our hospital will be recognized for contributing to worldwide scientific research. Our patients will be treated more quickly. We will contribute to the national economy through clinical research funding, research related travels and inspections."

Pangaea’s partnership with Clinerion allows it to apply its machine learning algorithms to de-identified patient EHR data and unstructured doctors’ notes through Clinerion’s federated network of hospitals across 21 countries in Europe, Middle East, South America and Asia Pacific. Pangaea’s and Clinerion’s customers, scientists and clinicians from the Biopharmaceutical industry, will be able to find patients of specific phenotypes from across these different regions at speed and with higher accuracy.

Clinerion was selected as one of eleven SMEs (Small and medium-sized enterprises) from a pool of twenty-eight eligible applications to the first EHDEN pilot call this year, to be trained and certified, with the objective to speed up the process to map health data from various formats and institutions to the OMOP common data model.

For more information, please visit the EHDEN website.

The European Health Data & Evidence Network has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806968. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

More on EHDEN >

Clinerion Partners page >

“This partnership with EvidNet allows us to strengthen and expand our presence in Asia as well as collaborate with OHDSI, through our Partner, on the implementation of the OMOP CDM in the rest of Asia,” Says Ian Rentsch, CEO of Clinerion. “The core benefit of the partnership will be to provide accelerated access to treatments and visibility on clinical trials for patients in the Asian markets.

Clinerion offers Massive Bio access to oncology patient insights for site outreach and identification of cohorts for trial site selection and patient recruitment. Clinerion’s Patient Network Explorer queries anonymized patient data from its international network of partner hospitals to deliver real-world health data insights useful for Massive Bio’s site outreach programs.

View MassiveBio's website >

Eugen, a clinical development service provider based in Uruguay, will support Clinerion’s expansion by promoting hospitals in the country to join Patient Network Explorer (PNEx), adding to the platform true global representativeness. They will use PNEx to provide clients with solid real patient health data insights when choosing their clinical trial’s geographic distribution, better trial design tools and effective patient enrollment. Hospitals in Uruguay will increase their visibility and be in a better position to attract global multicentric trials while providing patients with innovative treatments.

“With this collaboration, we aim to have our own impact in the field of medicine and drug development, as well as contribute to the evolvement of the healthcare infrastructure in the country,” says Arman Babloyan, Director of the Arabkir Joint Medical Center & Institute of Child and Adolescent Health.

Semedy’s Clinical Knowledge Management System (CKMS) will empower Clinerion’s advanced Patient Network Explorer to integrate, manage and maintain multilingual terminologies, ontologies, and data dictionaries provided by Clinerion’s different hospital partners around the world.

As part of the partnership, PPC will use the Patient Network Explorer platform to advance clinical trials, trial enrollment, and accelerate global studies conducted in the People’s Republic of China, the Republic of China (Taiwan) and the Republic of Korea (South Korea). PPC will encourage hospitals to participate in Clinerion’s Patient Network Explorer platform for generation of RWD/RWE and bringing more global studies to hospitals.

“With the Clinerion database system, there will be a great progress in research at our center, facilitating patient selection and increasing our effectiveness. Today, a database and facilitating access to information are fundamental to the evolution of research”, says Dalton B. Precoma (M.D; Ph.D), cardiologist of Hospital Angelina Caron.

According to the Aging Analytics Agency's recent report, a lean political system and a strong research environment for GeroScience and for digital health are some of the main reasons explaing why Switzerland has one of the best life expectancy in the world (#2 overall with 83.4 years). Getting more homogeneous national health data still remains a challenge.

> View full report (more than 500 pages, free access) 

To access the full report, sign up on Aging Analytics Agency's website - it only takes a few seconds.

This new partnership will allow to build a holistic view of cancer treatment. 

We are proud to be a piece of this puzzle, as we already partner with O.I.s) to build a larger database which not only consists of e-health records data, but also of clinical trial related data. 

3 technologies, 1 purpose:

• We will leverage our Patient Network Explorer (PNEx): 19 countries, 100+ hospitals, 80 million patients
• O.I.s) will leverage its RWD database, TherapyMonitor, which consists of more than 5,000 treatment courses from 200+ institutions
• Andaman7 will use its App to gather patient-reported treatment experience in daily life.

...Connecting these tools will allow to generate unique real world evidence (RWE) to see what really works for patients, and create better patients' outcomes and experience. 

> View infographics

The partnership between Clinerion and Volv Global brings benefits to patients by combining Volv’s uniquely accurate cohort identification algorithms with Clinerion’s growing data network of hospitals around the world. The Volv and Clinerion partnership will deploy Volv’s inTrigue algorithms across many more hospitals and this will create tangible outcomes for patients who suffer from late diagnosis of between seven and 15 years, as well as from misdiagnosis and subsequent increased disease burden.

The partnership between Clinerion and OncologyInformationService (O.I.s) will create a platform for oncology which integrates O.I.s’ real-world databases with Clinerion’s patient data network, via Clinerion’s patented patient data analytics technologies. The partners aim to establish a real-world evidence (RWE) database from a network of cancer treating institutions which will also allow real-time query of the participating institutions’ electronic medical records (EMRs). 

“We at JCDC are delighted about partnering with Clinerion as there is an ideal alignment of Clinerion’s innovative technology and our clinical research expertise,” says Pathik Divate, CEO of the JCDC. “We are excited about harnessing the power of this technology to leverage our diverse patient population and bring in further efficiency in patient recruitment.”

With the hospital joining Patient Network Explorer, patients at Geniko Nosokomeio Thessalonikis “Papageorgiou” will be matched to clinical trials being run by international pharmaceutical companies on innovative medical interventions, as well as those being run by the hospital’s own academic researchers. This gives patients and physicians at the hospital access to leading-edge treatment options and supports the acceleration of the introduction of these treatments into the market.

Which industry is lagging behind the most in terms of digitization? Right, it is the healthcare industry! But who would have expected the usual lamentation of why this is the case; blaming regulatory constraints, scarce innovation culture, or unachievable technology barriers proved wrong. The appetite for change and finding new ways of doing things was too strong among Basel’s Healthcare innovators at the DayOne Expert Session on “Next Generation Digital Trials”.

Read the event's key takeaways [via BaselArea] >

The European Health Data & Evidence Network (EHDEN) recently achieved an important milestone in the effort to tap into the potential of real-world data and realise its mission to develop a federated network, standardised to a common data model. This will ultimately result in a Europe that more smartly manages and shares research methodologies - and expands education in open science and collaboration.

In concluding its first open call to SMEs (Small & Medium-sized Enterprises) to apply for training and certification, EHDEN has paved the way for speeding up the process to map health data from various formats and institutions to the OMOP common data model.

Eleven SMEs have been selected from a pool of twenty-eight eligible applications. The first wave of training will begin this month for five of the SMEs, with the other six following closely thereafter.

Prof. Peter Rijnbeek, Erasmus Medical Center, Rotterdam, The Netherlands and Coordinator of EHDEN, said, “We warmly welcome this initial group of SMEs. EHDEN provides SMEs with free training and certification, an ability to expand their market presence, and to be part of a transformational initiative that will have positive impact on patient outcomes across Europe.”   

“Establishing this first geographically diverse SME network is a critical step in building an eco-system that supports a range of data partners and other stakeholders in mapping and using health data,” said Nigel Hughes, Janssen Scientific Director RWD/WRE, and Co-Lead of EHDEN. “Once certified, these SMEs, together with the data partners that will be joining in the coming months and years, will become a key part of the EHDEN community,” he added.

For more information, please visit the EHDEN website.

The European Health Data & Evidence Network has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806968. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

More on EHDEN >

Clinerion Partners page >

The Real World Data for the course will be sourced from a subset of the de-identified electronic health records of patients in Clinerion’s hospital network. DIU Master’s students will gain access to Patient Network Explorer, Clinerion’s platform for secure, cloud-based query of remote, de-identified hospital patient data.

The Chilean company B-TRIALS, a specialist in providing tools and solutions in the health area, will be responsible for the expansion of Clinerion in Chile. This will give patients in Chile quicker and better access to innovative medical treatments via increased participation in clinical trials, and via accelerated product launch due to more efficient patient recruitment for clinical trials.

Separately and in combination, Clinerion and 2 GL’s services will accelerate access for patients and hospitals to next-generation medical treatments. Patients in the region will become more visible to sponsors for trial recruitment, and hospitals in the region will become better placed to run clinical trials. This ultimately accelerates drug launch

Download the PDF for the full release.

The Medison network of clinics specializes in outpatient and dental services for all social strata, focusing on patient health care, disease prevention, and timely and correct diagnosis. The four clinics in Tbilisi, Georgia, provide medical care to over 6,000 patients each month.

The network has highly qualified, specialist clinical staff and is fully equipped for state-of-the-art clinical trials. Medison currently has several trials running. “We are determined to provide our patients with the best possible care and we are deeply convinced that this partnership with Clinerion will help us achieve this,” says Tsotne Sherozia, Director of Medison. “Patient Network Explorer will give our patients access to the most innovative drugs in development, worldwide.”

EMC Szpitale operates 11 hospitals and 19 outpatient clinics, providing primary and specialized medical care to over one million patients across Poland. EMC Szpitale specializations include advanced diagnostics to comprehensive hospital treatment in gastroenterology, rehabilitation, urology, orthopedics, general surgery, gynecology, obstetrics and geriatric care. Currently, the hospital group is running 37 different clinical trials. 

 “We care for our patients. Everyday. In a better way. That’s why we work to increase interest and enrollment in clinical trials to ultimately ensure greater availability of innovative therapies for our patients,” says Anna Szewczuk-Lebska, spokesperson for EMC Szpitale.

"When it comes to understanding the patient experience, the main tools are surveys, interviews (and focus groups) and patient shadowing. In this article, we would like to focus on how querying of de-identified patient electronic health records (EHRs) can provide its own trove of data on the patient experience, particularly the patient journey and outcomes. EHRs are de facto patient-centric, and analysis of EHRs can offer key directions for recruitment, engagement and retention". 

©www.jforcs.com

Download to read full article >

The partnership between Inpharamo and Clinerion is grounded on the success to-date of the alliance established by Semicrol and Clinerion in September, 2018, which has enabled the integration of the functionality of Clinerion’s Patient Network Explorer with that of Semicrol’s Fundanet CTMS (clinical trial management system). This has provided a new tool for Fundanet users that improves the process of identifying candidate patients for clinical trials. 

Ian Rentsch, CEO of Clinerion, and Ricardo Márquez, Medical Director of Inpharamo, will officially launch the partnership during the second edition of the International Congress of Clinical Research, Mexico, to be held from May 16th to 18th, in Guadalajara (Jalisco). 

PDF File: Download Full Press Release (English Version) >

Czech Clinical Research Institute (CCRI) is a full-service contract research organization providing tailor-made solutions for clinical trials monitoring, project management and Good Clinical Practice auditing services, operating mainly in the Czech Republic and Slovakia.

“CCRI is a great match for Clinerion in the Czech Republic and Slovakia, traditionally countries with high medical expertise and infrastructure but low trial participation,” says Ian Rentsch, CEO of Clinerion. [...]

Following our recent partnership with Clinart, expanding our reach to the Middle East countries, Outsourcing Pharma has released an article which sums up Clinerion's recent progresses, as our international network has tapped into new countries where patients are still often underserved by clinical research at the moment. 

Read the Full Article on Outsourcing Pharma's website >

Bioforum is a data-focused Contract Research Organization (CRO), offering a wide range of consulting services, including medical writing, data management and bio-statistical support.

“We are extremely excited to launch this collaboration and are confident that together we can promote clinical research in our target markets. We are keen to introduce more medical centers to Clinerion’s advanced technology,” says Bioforum’s President & Co-Founder, Mr. Amir Malka. [...]

Download the PDF for the full release

Clinart has a strong position as an innovative, leading regional contract research organization offering a full-service end-to-end solution and access in the MENA region. Clinart will support Clinerion by linking sites and hospitals to the global network on Clinerion’s Patient Network Explorer (PNEx) platform. This will help hospitals in the region be more visible and accessible for global trial sponsors and attract more studies to the region. Clinart will also offer services derived from PNEx for the running of local real-world evidence studies and academic research.

The collaboration will initially focus on the Gulf countries of the United Arab Emirates and Saudi Arabia. This will expand later to other countries in the region [...] 

Download the PDF for the full release

[UPDATED 15.04.2019 - New article by Express Healthcare]

Randy Ramin-Wright, our International Business Director, spoke on “Improving Healthcare Outcomes with Real-World Data ecosystem throughout India” and how patient outcomes could be improved, new treatments could be brought to patients faster and the use of world evidence to support healthcare decision making. 

Read full article from Express Healthcare >

[09.04.2019 - Article by BioSpectrum]

BioSpectrum India published a paper wrap-up of the event explaining how Switzerland and India can collaborate to support healthcare education, research and innovation. 

“Traditional trial countries in Europe and North America are in high demand and may be somewhat saturated, with clinical trials competing for the same patient population. However, regions like Asia offer attractive untapped potential.[...]" - our International Business Director Randy Ramin-Wright has joined other experts to discuss how a Real World Data ecosystem can be introduced in India. 

Read full article from BioSpectrum > 

View Digital Health Conclave event >

Alpha MD is a global clinical research and technology consultancy that provides end-to-end solutions to healthcare partners.

With this partnership, patients in India will gain better access to clinical care as the Patient Network Explorer draws international clinical studies to the country, directly to the patients who will benefit most from participation in trials. Patients will also benefit from the efficiencies created in the clinical research process by Patient Network Explorer which contribute to getting drugs faster to market. Patient Network Explorer’s efficiencies include accelerating study protocol development, identifying suitable trial sites, and speeding up patient search and identification for trial enrollment.

Clinerion and Alpha MD's partnership was launched via our participation to the Digital Health Conclave in Bangalore.

View Digital Health Conclave event >

View Event Press Article >

Download the PDF for the full release.

Sigmasoft is a medical software company based in Greece and Cyprus with six years’ experience in eHealth. The company provides innovative software systems and consulting services for healthcare providers, institutions and pharmaceutical companies.

As part of the partnership, Sigmasoft will support Clinerion in integrating healthcare institutions and physicians in Clinerion’s international Patient Network Explorer platform, expanding clinical research opportunities for patients in Greece and Cyprus.

Download the PDF for the full release.

Szpital Specjalistyczny w Brzozowie, (the Specialist Hospital in Brzozów), Poland, specializes in oncology, hematology and cardiology. The hospital has 485 beds and electronic hospital records for more than 250,000 patients. Each specialization has its own Primary Investigator and research team and the hospital runs roughly 30 trials per year.

Download the PDF for the full release.

The University of Debrecen, Clinical Center, has a strong reputation for clinical research, currently running over 360 trials, with 113 starting in 2018, alone. The University is a “Global Prime Site” for IQVIA, a “Premier Site” for Sanofi, and has partnership with several CROs, pharma companies (incl. Pfizer, Novartis, ICON, Parexel).​

The University of Debrecen will have a higher profile with sponsors and gain participation in international trials of leading-edge medications by being visible on Clinerion’s Patient Network Explorer platform. Patients at the university will gain access to leading-edge medical treatments as a result.

Download the PDF for the full release.

Original publication date: February 28, 2019.

"Clinerion is expanding access to international clinical studies with the help of the Georgian medical software company, Medsoft. ”

Click here to read the article > 

Georgian Medical Software – MEDSOFT, an EHR systems supplier with 10 years’ experience in eHealth in Tbilisi, Georgia, supports hospitals and the medical community with innovative technology and dedicated services. More than 40 hospitals and medical centers in Georgia use MEDSOFT’s software. Their MEDWORK hospital information system (HIS) is integrated with the Georgian Ministry of Health, financial systems, and laboratory information systems, allowing costless and effective information management for the healthcare community.

As part of their partnership, MEDSOFT will support Clinerion in integrating hospitals in Georgia in Clinerion’s international network of partner hospitals on its Patient Network Explorer platform.

Download the PDF for the full release.

Citeline, part of the Informa Pharma Intelligence family, and Clinerion, today announced a partnership between the two companies providing clinical researchers with a more holistic method for making more evidence-based decisions during their clinical trial processes.

Meet Clinerion and Citeline at SCOPE 2019 >

Download the PDF for the full release.

"Enabling access to real-world data on a global scale is daunting, but surmountable by applying a new collaboration model with innovative technologies for consolidation of data."

This article is taken from European Pharmaceutical Contractor February 2019, pages 39-42. © Samedan Ltd.

Link to the article in European Pharmaceutical Contractor >

North Estonia Medical Centre (NEMC) consists of seven clinics and 32 specialist centers, and is the most important caregiver in the capital of Estonia, Tallinn, as well as in the northern part of the country. As a tertiary care center, it covers two thirds of the population of Estonia. NEMC’s team has over 4000 doctors, nurses, caregivers and other specialists. Over 500 of them are doctors and more than 150 are medical residents.

NEMC has a leading expertise in clinical trials in Estonia, where continuous education programs about GCP and clinical trials methodology have been provided for many years for different target groups – investigators, pharmacists, nurses and study coordinators. 

NEMC currently runs about 85 clinical trials per year, 25 of them begun in 2018, with the capacity and expertise to run many more.

Download the PDF for the full release.

“Together with our partner, iHealth, Clinerion is in the process of a significant push to encompass coverage of the majority of patients in Brazil,” says Clinerion CEO Ian Rentsch. “Santa Casa da Misericordia represents an important addition to Clinerion’s network of partner hospitals in the country, the region, and the world.”

"Santa Casa has a long tradition in Clinical Research and the Clinerion / iHealth Patient Network Explore will help us maintain leadership in this area,” says Dr. Jorge Hetzel, Medical Director for Teaching and Research.

Download the PDF for the full release.

Visitors to Clinerion’s website may now see a dynamic visual representation of its patient network on a map. The map shows locations, by country, and numbers of patients. When searched for a disease indication, the map shows a heatmap representation of the prevalence of the searched term, including partial matches. The user can then select a particular term to see its prevalence displayed on the map. This heatmap is linked directly to Clinerion’s Patient Network Explorer platform and shows live data from Clinerion’s international network of partner hospitals.

Alongside the map, visitors can also see the current global coverage of Patient Network Explorer, in terms of numbers of patients, sites and countries. These metrics reflect the current state of data on Clinerion’s network of partner hospitals and other data partners.

Download the PDF for the full release.

"Using modern digital technologies, today’s research networks are embracing new ways of more intimate collaboration and constructive improvisation to increase the speed and quality of clinical research"

This article is taken from International Clinical Trials November 2018, pages 22-25. © Samedan Ltd.

Link to the article in International Clinical Trials November 2018 >

Clinerion is moving to new offices in Basel, Switzerland. Following strong expansion in its business, the company is in the process of growing its global team. In the six months leading up to the start of 2019, the company expects to have added several additional new positions. Staffing is increasing in all areas of the company, from Customer Solutions to Site & Patient Network Development, from Software Development to Data Analytics and Marketing.

Clinerion’s new offices have nearly double the floorspace of its old premises, matching the increased requirements of its expanding business. The company’s headquarters remain in Basel, Switzerland, the major worldwide hub for the pharmaceutical industry, and global headquarters of two of the world’s top ten pharma companies. From here, Clinerion’s analysts will tap into and derive valuable insights from anonymized patient data throughout its network of hospital and data partners.

Download the PDF for the full release.

S4 Research, with its wide network in India and its deep experience in the clinical trials space, will support Clinerion in the expansion of its global network of partner hospitals in India.

Download the PDF for the full release.

Athens Medical Group (AMG) runs eight ultramodern hospitals in Greece, seven in the Athens Metropolitan Area and one in Thessaloniki, Northern Greece. AMG cooperates with an extensive nationwide network of 390 diagnostic centers, eight haemodialysis units and a growing network of official associate centers throughout Greece. A multinational company, it operates Medsana clinics, four modern and specialized diagnostic centers in Romania, which also have presence, through affiliate companies, in North Africa, the Balkan area, Russia and the Former Soviet Union countries.

Joining Clinerion’s Patient Network Explorer platform will bring more innovative treatments to the patients of Athens Medical Center’s hospitals and clinics, and give their physicians more options in treating their patients. The group will also gain more exposure to global clinical trials run by international pharmaceutical companies and contract research organizations.

Drug developers working on innovative treatments will now benefit from access to new geographies and clinics with strong therapeutic focus.

Download the PDF for the full release.

Original publication date: September 11, 2018.

"The collaboration will integrate the functionality of Clinerion's Patient Networlk Explorer with Semicrol's Fundanet clincial trials management system (CTMS).”

Click here to read the article > 

The technical and commercial collaboration between the two companies will integrate the functionality of Clinerion’s Patient Network Explorer with Semicrol’s Fundanet Clinical Trials Management System (CTMS), enabling the automated, efficient sharing of patient data from a hospital’s electronic health records system to the CTMS running a clinical trial at that hospital.

The collaboration will give clinical trial sponsors and managers unified tools to manage trial data and workflows throughout the clinical trial process, from planning to reporting of results. This will enable a broader approach in clinical trials, drug development support and better outcomes for patients. Patient data privacy is preserved, and patient data remains within the hospital IT infrastructure throughout.

Clinerion and Semicrol will attend BIOSPAIN together >

Semicrol Press Release (Spanish) >
Semicrol release on the Semicrol site >
Semicrol release on the Fundanet site >

Download the PDF for the full release.

Original publication date: September 4, 2018.

"To improve clinical trial design, site selection, and patient enrollment, the real-world data solutions firm Clinerion is partnering with Patient iP, a health data and analytics company.”

Click here to read the article > 

The companies will collaborate using Clinerion’s intelligent, patented Patient Network Explorer platform and Patient iP’s proprietary daTAscape asset to better target clinical trial sites and accelerate trial enrollment on a global scale. Clinerion aggregates healthcare information across institutions and geographies from their global network of partner hospitals, creating one single comprehensive real-time view. Clinerion’s network currently includes more than 16 million real time patient lives, with an additional 55 million lives contracted and in implementation, across more than 100 hospitals in the Americas, Europe and Asia. Used in combination with Patient iP’s platform which contains more than 16 million ambulatory electronic medical records (EMR) across 5,000 practice sites, the partnership will bring remarkable improvements to clinical trials.

Download the PDF for the full release.

"Teaching hospitals and academic institutions which band together to conduct research reap the benefits of the increasing digitalisation of healthcare. In this article, we examine the attendant benefits and challenges, with particular focus on electronic health records and the privacy issues relating to patient data. We review the permissions-based sharing model for patient data as an optimal solution which allows flexibility in adapting the individual hospital’s digital infrastructure to the challenges and needs of different types of research networks and projects."

Link to the article in Journal for Clinical Studies, Volume 10, Issue 4 >

The Hygeia Group comprises three hospitals:

• the Hygeia hospital, a diagnostic and therapeutic center and general hospital in Athens, Greece with 315 beds;
• the Mitera Hospital, a general hospital specializing in maternity, gynecology and children’s health in Athens, Greece with 459 beds;
• the Leto Hospital, a maternity and gynecology hospital, and surgical center in Athens, Greece with 100 beds.
   

The Hygeia Hospital is the only hospital in Greece with a Joint Commission International (JCI) Gold Seal accreditation for quality and safety in healthcare. The group currently conducts above 80 clinical trials per year.

Download the PDF for the full release.

“Clinerion’s established approach fits very well with the direction we have been pursuing,” says Professor Sang-Heon Lee, Head of Korea Precision Medicine Development Group and Professor at Korea University Medical Center. “We are very pleased with the reliability and scalability of their solution. As South Korea has very strict patient privacy regulations, we are also happy to see their in-built protections for privacy.”

Download the PDF for the full release.

First Hospital, Tbilisi, is considered one of the best sites in Georgia by contract research organizations (CROs) running clinical trials due to the quantity of screened patients. The hospital serves the Tbilisi area (population: 1.2 M) and has 100 beds. It works in emergency medicine, critical care, general surgery, gynecology, traumatology, orthopedics, cardiology, anesthesiology, neurology, colon and rectal surgery, angiology, internal medicine, neurosurgery, transfusiology, and neonatology, with a specialization in intensive care, incl. for clinical trials.

Download the PDF for the full release.

"UHC Zagreb (in Croatian: Klinički bolnički centar (KBC) Zagreb) has 1,800 beds. The hospital conducted 51 clinical trials in 2016 and 61 in 2017. It has 39 Principal Investigators and an additional 120 doctors working on trials.

"By joining Clinerion’s network of partner hospitals, UHC Zagreb brings its patients and clinicians access to the latest innovative medical treatments being developed by the pharmaceutical industry. Clinerion’s clients, international pharmaceutical companies and contract research organizations, use Clinerion’s technology solution to establish the availability and location of populations of eligible patient cohorts for enrollment in clinical trials. Clinerion’s technology makes it easy and reliable to assess whether patients of a partner hospital match the inclusion / exclusion criteria in a trial protocol."

Download the PDF for the full release.

The main focus was to explain the technology driven processes of the recently established Clinical Trials Center. Principal investigators and study teams can now make data driven feasibility, patient identification and protocol optimization using Clinerion’s technology solutions. Researchers can also leverage the technology to make faster publications. 

Read our full report on the event, here >

The main focus was to explain the technology driven processes of the recently established Clinical Trials Center. Principal investigators and study teams can now make data driven feasibility, patient identification and protocol optimization using Clinerion’s technology solutions. Researchers can also leverage the technology to make faster publications. 

Read our full report on the event, here >

Clinerion organized this training seminar on March 17th in collaboration with Istanbul Mehmet Akif Ersoy Cardiovascular Surgery Training Hospital (IMAEH), Istanbul University Medical Faculty Pharmacology Department and IQVIA Turkey.

The seminar had the aim of improving the clinical research infrastructure in the hospital and had 80 participants, from hospitals, pharmaceutical companies and CROs. The training ended with an exam and certification for the successful participants. The certifications are approved by the Ministry of Health, and can therefore be used in appropriate applications. 68 participants successfully received certifications and one participant received a participation certificate.

Read our full report on the event, here >

Original publication date: March 20, 2018.

"Further footprint growth is underway, as the company plans to reach every continent and almost double the number of accessible patients to 310 million by the end of 2018.

“This global footprint, balanced in terms of geography and in terms of medical specialization, will allow our clients a comprehensive, varied and representative view of patients and trial sites around the world for all of their needs”

Click here to read the article > 

We are thrilled to welcome Ian Rentsch as our new CEO!

Rentsch brings more than 21 years of international experience in multinational pharmaceutical companies as well as in small/niche and global CROs.

Taking on leadership of Clinerion, Ian aims to solve the main industry challenge by bridging the divide between patients, sites, and drug developers.

“The company’s focus on electronic health data and innovative technologies allows it to reimagine how clinical research is conducted and how sites and patient communities around the world become engaged.” says Rentsch.

Download the PDF for the full release.

Original publication date: Febriary 14, 2018.

"HealthCarePoint has announced a mutual collaboration with Clinerion through which members of the company’s BlueCloud Sponsor Network will gain access to Clinerion’s patient database via a dynamic map."

Click here to read the article > 

"The Children’s Emergency Hospital "Louis Turcanu" brings over 90,000 patients in the Timișoara area to the PRS network of hospitals, expanding Clinerion’s global footprint into Romania."

Download the PDF for the full release.

"The integration of solutions for querying patient electronic health records with electronic data capture (EDC) technologies generates more comprehensive data for real-world evidence, creating new efciencies and improving data quality."

Link to Journal for Clinical Studies, Volume 10, Issue 1 >

"HealthCarePoint, a Texas-based health care and clinical research networking-technology company founded by patient-survivors, today announced its mutual collaboration with Clinerion. The collaboration will further both companies’ shared mission of transforming clinical trials by expanding access to patient data analytics services.

"Members of the BlueCloud Sponsor Network will be able to view the locations and numbers of Clinerion’s patients on a dynamic map. Drill-downs allow the user to narrow the selection by therapeutic area and indication. Clinerion is expanding its global coverage rapidly and will keep the patient map up-to-date. With 76 Sponsors currently in their network, managerial healthcare professionals will now be able to search tens of millions of patients around the world on Clinerion’s PRS platform by therapeutic area and indication."

Read the full press release on PRWeb/Cision >

Here is the statement by Clinerion's International Business Director, Randy Ramin-Wright:

"Today, I have the pleasure to announce that our partnership with ASUS Life has reached a new milestone, as the Show Chwan Hospital Group is joining Clinerion’s global network of hospitals. This represents a major step forward as Show Chwan is the first hospital in Taiwan to join Clinerion’s hospital network.

"With this step, Show Chwan demonstrates once again its commitment to innovative technologies for the advancement of clinical research and the care of its patients. We are thrilled about the prospect of a long-term relationship with the Show Chwan Hospital Group and helping them extend their international sponsored clinical trial program.

"Our objective is to bring innovations in medicine to ever more patients around the world. To do this, we need support and coverage from leading, high-technology hospitals with an excellent clinical reputation across the globe. In this sense, Show Chwan is a key, invaluable partner.

"ASUS Life, as Clinerion’s partner in Taiwan, is uniquely positioned to help realize this goal. With its existing global ASUS Cloud infrastructure, ASUS Life is ideally able to provide comprehensive and cutting edge data solutions for the healthcare domain. We are delighted to have ASUS Life as our partner and are confident our partnership will translate into major advances in Taiwanese healthcare!"

"Bioserv SMO manages trial sites in the Rio Grande do Sul region of Brazil. The first implementation of PRS will take place at the Hospital São Vicente de Paulo, in the city of Passo Fundo. São Vicente de Paulo has 600 beds, and its hospital information system holds 540K patient lives.

"The hospital’s 26 Principal Investigators specialize in multiple therapeutic areas, running studies in Phase Ib, II, III and IV on drugs and medical devices. Currently, they have 60 ongoing studies."

Download the PDF for the full release.

Original publication date: November 27, 2017.

"Clinerion has expanded its patient recruitment system (PRS) platform [in Estonia and Turkey] to provide its clients, pharma companies, and contract research organizations (CROs) greater access to potential clinical trial participants."

Click here to read the article > 

"The hospital has a catchment area which covers ~50% of the Estonian population. It performs 40,000 inpatient treatments and receives 400,000 outpatient visits annually.

"Tartu University Hospital is the pioneer of e-Health in Estonia. 80% of its medical data communication is digital.

"Tartu University Hospital currently runs 30-40 clinical trials per year, with capacity to do many more, and the expertise to back it up. By joining, the PRS platform, the university hospital’s clinical trials facilities will be exposed to a wide range of global clinical trials run by Clinerion’s clients, international pharmaceutical companies and contract research organizations."

Download the PDF for the full release.

IMAEH will have more than 600 beds in 2018, including an intensive care unit with 174 beds. With PRS IMAEH will be able to identify and recruit patients also in an emergency setting. IMAEH adds more than 2 million medical records and 260,000 patient lives to PRS.

Download the PDF for the full release.

Original publication date: October 30, 2017.

"Clinerion has partnered with Provisio Inc. to expand its service coverage in the Americas by approximately 60m patients."

Click here to read the article > 

Original publication date: November 2, 2017.

"Through a new collaboration with Provisio, Clinerion can now reach over 60 million patients in the U.S. for potential clinical trial recruitment and real-world evidence data generation. This marks a major step forward for the company’s effort in the past 12 months to expand the reach of its patient recruitment system (PRS) around the world."

Click here to read the article > 

Clinerion now has a truly global footprint for its services for clinical trial patient search and identification, and data generation for real-world evidence and market access activities.

Download the PDF for the full release.

Hospitals using FHIR may now directly exchange data with Patient Recruitment System without the need for additional implementation effort.

Download the PDF for the full release.

Original publication date: September 5, 2017.

"Ulf Claesson is a "serial entrepreneur". During the past 25 years, he has set up companies that have gone on to become firmly established in the market. In 2012, he joined Clinerion as CEO and shareholder. Since then, the company has positioned itself in the medical data field and recently entered into a partnership with British company Cisiv. Clinerion's software helps recruit patients for clinical trials run by major pharmaceutical companies – in real time. But the competition never sleeps. A growing number of competitors is now appearing, especially in the USA where there is no shortage of risk capital. In this interview for the Innovation Report, Claesson explains how the Basel-based healthtech company plans to maintain its leadership position ..."

Link: www.baselarea.swiss/baselarea-swiss/channels/innovation-report/2017/09/In-Switzerland-we-often-sell-promising-technologies-too-early.html

"The Patient Recruitment System (PRS) web application has been completely redesigned, using state of the art web design principles based on Material Design. It now incorporates new functionalities and improvements in ease-of-use, resulting in a modern, visually attractive, intuitive and user-friendly appearance. The entire application can now be used on touch displays ..."

A new look for the Protocol Designer.

​Results in graphical format by age and gender.

Download the PDF for the full release.

Original publication date: August 23, 2017.

"Permission to use electronic patient data differs from country to country, and can also depend on the interpretation thereof by hospital authorities.  This limits the pool of hospitals which can be called upon for online patient recruitment for clinical trials.

"With Clinerion’s ANID technology, all these concerns are automatically allayed, because the technology only uses anonymized data ...

"To our knowledge, there are no other patient recruitment solutions which work using fully anonymized data."

​Link: www.outsourcing-pharma.com/Clinical-Development/Clinerion-patents-anonymized-identification-technology

• “Anonymized identification” is based on fully anonymized patient records, with no use of pseudo IDs.
• PCT patent filed for a new technology which uses a combination of techniques to match anonymized records with corresponding hospital medical records.
• New system set-up increases data security and privacy protection.
• Technology can be applied in the identification of clinical trial candidate patients within trial sites.

Visit the new patent page >

Download the PDF for the full release.

"Clinical research is underdeveloped in Brazil, although the country has the requisite expertise and infrastructure. We examine the situation and trends in South America and Brazil. In particular, we look at two developments which promise the acceleration of clinical research in Brazil. First, the approval in the Senate of the PLS 200 law, which gives a framework for making clinical trials approvals more efcient. Second, the initiatives for digitisation of health data, which permit the use of new patient data analytics technologies."

Link to Journal for Clinical Studies, Volume 9, Issue 4: www.jforcs.com/accelerating-clinical-research-brazil

Original publication date: August 3, 2017.

"Başkent University’s hospital cluster has joined Clinerion’s Patient Recruitment System (PRS) Platform, expanding sponsor access to potential clinical trial participants."

​Link: www.outsourcing-pharma.com/Clinical-Development/Clinerion-adds-4.5m-patients-to-recruitment-platform

"Precision medicine is fast becoming recognised as the way forward for the treatment of diseases. Having the right patient medical information is key, and IT technologies are crucial in being able to analyse it. Of all the data sources, electronic medical records seem to hold the most potential."

Link to August 2017 edition of International Clinical Trials: www.samedanltd.com/magazine/current/13

"With this move, Başkent University will gain the advantages of partnership with the Patient Recruitment System (PRS) platform: visibility to sponsors making trial siting decisions, increased speed and effectiveness in recruitment, increased efficiency in matching studies to the hospital’s own patient population. Sites can also make use of PRS, internally, for academic trials with the assurance of compliance to hospital-level data access permissions.

"Patients at Başkent University will be able to access the latest treatments and therapies offered by the running of clinical research trials for innovative medicines in development."

Download the PDF for the full release.

Original publication date: July 24, 2017.

"Two industry innovators have joined forces to take the lead in real-world studies. Clinerion and Cisiv have formed a groundbreaking partnership to offer a revolutionary approach to observational research by enabling automated data transfer from electronic hospital records (EHRs) to electronic data capture (EDC). The partnering of both companies’ patented technologies will reduce the data entry burden to physicians participating in observational studies, improve data quality and enable smooth and rapid data collection in real-world settings. Clinerion and Cisiv share a vision of using technology to make real-world research leaner, easier to implement and, ultimately, more cost-efficient."

CWWeekly is only available to subscribers.

​Link: www.centerwatch.com/news-online/2017/07/24/centerwatch-weekly-july-24-2017/

Two industry innovators are joining forces to take the lead in real-world studies.

Visit Clinerion's Partners page >

Download the PDF for the full release.

Original Publication Date: July 3, 2017.

"Though Brazil has the expertise and infrastructure, clinical research is not at the level that might be expected of the world’s fifth-most-populous country. Luis Magalhaes and Le Vin Chin examine the challenges and two developments that promise to improve the situation: the approval of the PLS 200 law, to smooth clinical trials approvals, and the digitalisation of health data, enabling patient data analytics."

Link: www.pharmaphorum.com/views-and-analysis/accelerating-clinical-research-brazil

Press release: Clinerion enters South America, as Brazil’s iHealth Group joins the Patient Recruitment System platform >

Report: “Accelerating Clinical Research in Brazil” Seminar​ >

"The potential for the pharmaceuticals industry in the Middle East is vast, and growing. Clinical research is also growing, alongside pharma, in the region, despite variations in situation from country to country, and despite certain barriers that still need to be solved. The challenges of regulations and patient recruitment, in particular, are analysed. We take a specifc look at one of the most established countries in the region for clinical trials, Turkey, to see how it might act as a model for the rest of the region."

Link to Journal for Clinical Studies, Volume 9, Issue 3: www.jforcs.com/regulations-recruitment-experiences-middle-east

©www.jforcs.com.

Link: www.s-ge.com/en/member-month

Original publication date: May 24, 2017.

"Digitalisation in the health sector is in full swing. Switzerland is well positioned, but must be careful not to be overtaken by old and new competitors, according to serial entrepreneur Ulf Claesson. Active himself in this field with Clinerion, Claesson knows the situation first hand ..."

Link: www.startupticker.ch/en/news/may-2017/in-switzerland-we-are-not-aggressive-enough

Taking the supposed date of the very first clinical trial, for scurvy, by ship surgeon James Lind, aboard the HMS Salisbury, International Clinical Trials Day celebrates the practice of clinical trials itself, as well as recognizing the practitioners whose efforts contribute to the advancement of medicine and public health. The Day also acts to raise awareness among the general public on the benefits of the practice.

Link (ACRP): www.clinicaltrialsday.org
​Link (ECRIN): www.ecrin.org/event/international-clinical-trials-day-2017

On Monday, May 15, 2017, Clinerion ran a seminar on “Accelerating Clinical Research in Brazil” with the support of the Consulate General of Switzerland, in São Paulo.

The event was very well attended and featured speakers across the field of clinical research, which included the Brazilian association for Clinical Research, Aliança; the Patient Society of Multiple Sclerosis, ABEM; the iHealth Group; and the International Clinical Trial Center Network, ICN.

Attendees included representatives from several public and private hospitals, the president of the Brazilian Federal University Hospitals Network (EBSERH), CROs and pharmaceutical companies. 

The event allowed the attendees to exchange and discuss the great, new opportunity for the Brazilian clinical research community to expand its role as a major world player in the field of clinical research with the passing of the "PL200" law in the Brazilian Senate; and the exciting tools, techniques and technologies which are the way forward.

Read our full report on the event, here >

"Clinerion will be running an open seminar event in São Paulo on May 15th, 2017, presenting cutting-edge techniques and technologies which can increase the speed, efficiency and competitiveness of Brazilian clinical trials. The event is supported by the Consulate General of Switzerland in São Paulo, and will take place at the official residence of the Consul General."

See the event on our Events page >

Download the PDF for the full release.

"The problem defined: Any prospective new drug must successfully pass a succession of three clinical trials phases, before it can apply for market approval.

"These trials represent a significant investment for a pharma company and, as they are prone to delays and can even fail altogether, they put immense financial pressure on them.

"One of the root causes for the failure of trials is the inability to recruit the specified number of eligible patients in the foreseen time span. Delays in the market launch can amount to as much as US$8 million per day for a blockbuster drug in opportunity costs for a pharmaceutical company."

Link: www.worldpharmatoday.com/Articles/overcoming-the-challenges-of-clinical-trial-recruitment-using-big-data-technologies

“Clinical trials bring many benefits to a country’s economy, to hospitals, physicians and patients,” says Clinerion’s newly appointed Head of EEMEA Region, Bariş Erdoğan, PhD. “Now, hospitals in the EEMEA region have the opportunity to take a share of the global market for clinical trials. Clinerion offers them an effective way to come to the attention of trial sponsors and bring new studies to their countries.”

Clinerion solutions for the EEMEA Region will next be presented in attendance at the "Emerging Markets Forum: Pharma and OTC go-to-market strategies, partnerships and market access" meeting in Berlin, Germany (March 13-14, 2017), and the Clinical Trials in Central and Eastern Europe conference in Budapest, Hungary (April 25-26, 2017).

Download the PDF for the full release.

Original publication date: February 20, 2017.

Link: http://www.outsourcing-pharma.com/Product-Categories/Phase-III-IV/Clinerion-enters-Asia-through-strategic-alliance-with-ASUS-Life

The new alliance between Clinerion and ASUS Life helps shorten the time it takes to bring a new drug to market, benefitting patients who get earlier access to new medicines.

With this collaboration, researchers at hospitals, pharmaceutical companies and contract research organizations gain real-time, EHR-based insight on the Taiwanese patient population. Eligible patients can subsequently be recruited by trial staff at Show Chwan’s 8 hospital sites. The collaboration will also enable the matching of patients with medications for rare and orphan diseases and the generation of data for real-world evidence analyses.

Download the PDF for the full release.

Original publication date: January 16, 2017.

"To strengthen its presence in this new market, Clinerion has forged a partnership with the iHealth Group of Brazil, which operates 40 hospitals, with a total patient population of 25 million. The iHealth Group’s role is to make consistent quality electronic health records (EHRs) data available, signifcantly broadening the number of patients who could potentially participate in trials.

Download the PDF for the full article.

Original Publication Date: December 12, 2016.

“Before PRS, our study team recruited 15 patients in six months,” the Cardiology Institute respondent continued. “With PRS they enrolled 36 additional patients, which took less than two months and solely from screening only 15% of PRS’s patient list.”

Link: www.appliedclinicaltrialsonline.com/solutions-driving-efficiency-clinical-trials

This article was based on Clinerion's recent white paper and case study, investigating feedback gathered from current users of Patient Recruitment System.

• White Paper: Clinerion’s Patient Recruitment System (PRS): A big data solution for patient recruitment for more effective and cost efficient clinical trials. >
• Case Study: Healthcare User Experience: Clinerion Patient Recruitment System (PRS). >

Clinerion’s Patient Recruitment System (PRS) Patient Finder tool has a wealth of health data which can now be harnessed to guide pharmaceutical companies in their R&D and commercial decision making by providing information on the prevalence of target diseases and the distribution of patient populations.

Download the PDF for the full release.

"Ulf Claesson provides a fascinating and passionate account of how his firm is aiming to remove ‘guesswork’ and estimations for medical practices whilst highlighting interesting developments in the global clinical research industry."

Note: this article is free to read, but behind a registration wall.

Link: www.pharmaboardroom.com/interviews/interview-ulf-claesson-ceo-clinerion-switzerland

Link: www.outsourcing-pharma.com/Commercial-Services/Clinerion-Patient-Recruitment-System-enters-South-America

With iHealth joining PRS, pharmaceutical companies and contract research organizations sponsoring clinical trials will gain real-time, EHR-based insight on the Brazilian patient population. Sponsors using PRS will be able to evaluate the distribution of eligible patients at iHealth’s sites during the development of a trial protocol and site selection for their clinical trials. These candidates can then be identified and recruited by the sites, themselves. Access to patient data in real-time enables more effective and efficient recruitment, especially for time-dependent criteria. Patient data also becomes available for matching patients with medications for rare and orphan diseases and the generation of data for real-world evidence.

Download the PDF for the full release.

Link: www.worldpharmatoday.com/Articles/scalability-and-patient-data-security-in-the-age-of-clinical-trial-recruitment-using-electronic-medical-records-an-infrastructure-solution

The IU Dentistry School specializes in all fields of dentistry, from Oral and Maxillofacial Surgery to Prosthodontics, from Periodontology to Pediatric Dentistry, Endodontics to Orthodontics. The hospital treated over 97,500 patients in the past year.

“We see a great benefit for our patients as well as for our hospital,” says Prof. Dr. Gülsüm Ak, the Dean of the Dentistry School. “PRS will bring our patients access to innovative new treatments, while the Dentistry School will gain higher exposure and visibility for leading edge clinical research.”

Download the PDF for the full release.

Clinerion announces a new service and use case for its Patient Recruitment System (PRS). The PRS Patient Finder tool can now be used to give patients requiring personalized, precision, or orphan treatments access to new medicines earlier, and give physicians additional options in treating them.

With the new service, patients in “hard-to-reach” populations, such as patients with rare diseases and patients requiring personalized treatments, can be matched with new, targeted treatments. As patients with rare diseases are de facto very rare, connecting the patient to an innovative treatment is often very inefficient without a technological solution in place ...

Download the PDF for the full release.

The Clinerion-supported hospitals in Turkey will complete an online training program and earn Clinpal Readiness Certification. The training ensures each hospital has key stakeholders with the skills necessary to solicit, enroll and engage study patients through its use of the Clinpal technology.

Link to press release: www.businesswire.com/news/home/20161103006251/en/eClinicalHealth-Clinerion-Launch-Clinpal-Readiness-Certification-Hospitals

Link: www.outsourcing-pharma.com/Clinical-Development/Clinerion-patient-recruitment-system-compliant-with-privacy-directives

The expert concluded that Clinerion’s procedures for de-identification and pseudonymization meet the anonymization requirements set forth in international privacy directives, such as the Health Insurance Portability and Accountability Act (HIPAA) and the EU Data Protection Directive (95/46/EC) and judged them consistent with best practices to ensure that the risk of re-identification was sufficiently small, statistically.

Recent developments have shown the real benefits arising from the use of big data analytics techniques to interrogate EHR-databases at hospitals directly. With the right software infrastructure, eligible patients can be discovered based on complex combinations of query criteria, and in real-time. Trial managers can unearth more candidates, quicker.

But this development raises questions for patient privacy: using these electronic methods, are an individual’s personal details at risk of arriving in unauthorized hands?

In this paper, we examine the technological and legislative environments, analyse the ensuing risks, and propose some best practice methods for mitigating these risks.

Link to September 2016 edition of the Journal for Clinical Studies: https://issuu.com/mark123/docs/50_jcs_september2016_web

©www.jforcs.com.

We are working hard to bring even more new technology solutions to PRS, and to improve the user experience. Version 4 makes it even more useful and supportive of the needs of our users.

Clinerion.com has evolved to be better than ever! If you're reading this, you're already here - please have fun exploring the new site. We hope you enjoy the experience!

Clinerion will present their Patient Recruitment System, which makes patient recruitment for clinical trials quicker and more efficient, in a rolling series of webinars targeted at each region.

Go to the Clinerion webinars page >

Traditional methods of fnding suitable candidates for clinical trials are time-intensive and cost drug companies millions, putting the development of new medicines at risk and elevating prices. New techniques borrowed from big data analytics allow the process to be completed much more effciently.

Link to August 2016 edition of International Clinical Trials: www.samedanltd.com/magazine/13

The patent, “Semantic Interoperability System for Medicinal Information” (U.S. Patent US20130030827 A1, Publication date: January 31, 2013), is used in the semantic search and indexing component at the backend of Patient Recruitment System. This technology applies rules on semantic elements, mostly elements of medical terminologies, on how to link them with patient data for an improved and high-performance indexing and optimized search results.

Congratulations to our team!

Read more about our unique, patented technology >

The Business Intelligence Group has announced that Clinerion has been recognized as a Finalist in their annual Stratus Awards for Cloud Computing. The organization sought to identify the companies, products and people that are offering unique solutions that take advantage of cloud technologies ...

Business Intelligence Group Press Release: 26 Companies That Prove the Cloud is Dominating Globally.